Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Although the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia including patients with refractory/relapsed disease or with TP53 defect, 20% of patients still show disease progression, with BTK and PLCG2 mutations representing the predominant mechanisms conferring secondary ibrutinib...